Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsSeptember 15, 2026Biodexa Pharmaceuticals PLC, NASDAQ:BDRX (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unme…